100342-30-1

Basic information

• Product Name: N-tert-Butyl-2-thiophenesulfonamide
• Synonyms: N-tert-Butyl-2-thiophenesulfonamide;N-(1,1-Dimethylethyl)-2-thiophenesulfonamide;N-(tert-Butyl)thiophene-2-sulphonamide;2-Thiophenesulfonamide, N-(1,1-dimethylethyl)-;N-tert-Butyl-2-thiophenesulfonamide
• CAS NO: 100342-30-1
• Molecular Formula: C₈H₁₃NO₂S₂
• Molecular Weight: 219.32
• Product Categories: API intermediates;Thiophene intermediates
• Mol File: 100342-30-1.mol

Chemical Properties

• Melting Point: 82.0 to 86.0 °C
• Boiling Point: 321 °C
• Flash Point: 148 °C
• Appearance: /
• Density: 1.224
• Vapor Pressure: 0.000311mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C(protect from light)
• Solubility: soluble in Methanol
• PKA: 11.86±0.50(Predicted)
• CAS DataBase Reference: N-tert-Butyl-2-thiophenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butyl-2-thiophenesulfonamide(100342-30-1)
• EPA Substance Registry System: N-tert-Butyl-2-thiophenesulfonamide(100342-30-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 100342-30-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-tert-Butyl-2-thiophenesulfonamide is used as a pharmaceutical intermediate for the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be a key component in the development of new medications.
Used in Therapeutic Applications:
N-tert-Butyl-2-thiophenesulfonamide is used as an anticonvulsant and antihypertensive agent, leveraging its potential therapeutic properties to manage and treat these conditions.
Used in Drug Development:
N-tert-Butyl-2-thiophenesulfonamide is utilized in the research and development of new drugs for the treatment of various medical conditions, contributing to the advancement of pharmaceutical treatments.
Used in Industrial Applications:
N-tert-Butyl-2-thiophenesulfonamide is used as a corrosion inhibitor, demonstrating its potential to protect materials from degradation in industrial settings, thereby extending their lifespan and improving efficiency.

InChI:InChI=1/C8H13NO2S2/c1-8(2,3)9-13(10,11)7-5-4-6-12-7/h4-6,9H,1-3H3

Upstream product

• 16629-19-9 thiophene-2-sulfonyl chloride 
• 75-64-9 tert-butylamine 
• 6339-87-3 2-thiophensulfonamide 
• 507-19-7 t-butyl bromide 
• 691-64-5 di-tert-butyl oxalate 

Downstream Products

• 6339-87-3 2-thiophensulfonamide 
• 146013-28-7 N-(tert-butyl)-5-isobutylthiophene-2-sulphonamide 
• 477775-35-2 3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-N-tert-butylthiophene-2-sulfonamide 
• 147214-19-5 5-butyl-3-[(4-hydroxymethyl)phenyl]-2-(N-t-butylaminosulfonyl)thiophene 
• 1168076-29-6 5-(4-methoxyphenyl)thiophene-2-sulphonic acid tert-butylamide 

Relevant articles and documents

Zn- And Cu-catalyzed coupling of tertiary alkyl bromides and oxalates to forge challenging C?O, C?S, and C?N bonds

We describe here the facile construction of sterically hindered tertiary alkyl ethers and thioethers via the Zn(OTf)2catalyzed coupling of alcohols/phenols with unactivated tertiary alkyl bromides and the Cu(OTf)2-catalyzed thiolation of unactivated tertiary alkyl oxalates with thiols. The present protocol represents one of the most effective unactivated tertiary C(sp3)? heteroatom bond-forming conditions via readily accessible Lewis acid catalysis that is surprisingly less developed.

Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity

Mutating the side-chains of amino acids in a peptide ligand, with unnatural amino acids, aiming to mitigate its short half-life is an established approach. However, it is hypothesized that mutating specific backbone peptide bonds with bioisosters can be exploited not only to enhance the proteolytic stability of parent peptides, but also to tune its receptor subtype selectivity. Towards this end, four [Y]6-Angiotensin II analogues are synthesized where amide bonds have been replaced by 1,4-disubstituted 1,2,3-triazole isosteres in four different backbone locations. All the analogues possessed enhanced stability in human plasma in comparison with the parent peptide, whereas only two of them achieved enhanced AT2R/AT1R subtype selectivity. This diversification has been studied through 2D NMR spectroscopy and unveiled a putative more structured microenvironment for the two selective ligands accompanied with increased number of NOE cross-peaks. The most potent analogue, compound 2, has been explored regarding its neurotrophic potential and resulted in an enhanced neurite growth with respect to the established agent C21.

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I) wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings giv

NEW BICYCLIC ANGIOTENSIN II AGONISTS

There is provided a compound of formula (I) wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and ph

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of Formula (I), wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceuticalfy-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

NEW BICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I), wherein R1a, R1b, n, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I), wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings gi

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I), wherein the dotted lines, XI, X2, X3, X4, A, YI, Y2, Y3, Y4, ZI, Z2, R2 and R3

BICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS

There is provided compounds of formula I, wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z 1, Z2, R2 and R3 have meanings given in the description, and pha

Sulfonamides useful as carbonic anhydrase inhibitors

Sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.